Sanders Tri-Institutional Therapeutics Discovery Institute (TDI)

The Sanders Tri-Institutional Therapeutics Discovery Institute, a partnership among three world-renowned scientific and medical institutions, works to more effectively develop Therapeutics that arise from discoveries made in basic science labs. With a focus on early-stage drug Discovery, the Institute provides expertise in medicinal chemistry and compound screening, and conducts proof of concept studies needed to demonstrate that drug candidates can successfully alter the course of a disease. Specific research projects focus on alzheimers disease, sickle cell, osteoporosis, lysosomal, lipid deposits, parkinson's and basal cell carcinoma.

The Institute facilitates more efficient sharing of core facilities between the three partner institutions and forms industry partnerships with pharmaceutical and biotech companies to further advance drug research. It seeks to create intellectual property that can be further developed by an open field of industry collaborators. The majority of such services relate to medicinal chemistry support.